A product liability lawsuit was filed against Bristol-Myers Squibb and AstraZeneca by a woman who suffered heart failure and other severe cardiovascular complications alleging to be side effects of the saxagliptin-based diabetes drugs, Onglyza and Kombiglyze XR. The complaint was filed in the U.S. District Court for the Northern District of Alabama in early December. The lawsuits state that the defendants had knowledge that there was a significantly increased risk of adverse events associated with Saxagliptin, despite this they continued to manufacture, market, distribute, sell, and profit from the sales of Saxagliptin. A request for consolidating Onglyza lawsuits was made recently. The U.S. JPML is expected to consider oral arguments on the motion during an upcoming hearing in January 2018.